Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer

Cancer

Volumn 123, Issue 9, 2017, Pages 1528-1535

  Klaassen, Zachary ^a   Howard, Lauren E ^b,c   de Hoedt, Amanda ^b   Amling, Christopher L ^d   Aronson, William J ^e,f   Cooperberg, Matthew R ^g,h   Kane, Christopher J ^i,j   Terris, Martha K ^a,e   Freedland, Stephen J ^b,k  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

bone metastases; bone pain; metastatic castration resistant prostate cancer (mCRPC); prostate cancer; skeletal related event (SRE)

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; BLACK PERSON; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PREDICTION; PROSTATE BIOPSY; RISK ASSESSMENT; RISK FACTOR; SKELETAL-RELATED EVENT; BLOOD; BONE; BONE NEOPLASMS; CANCER GRADING; FRACTURES, SPONTANEOUS; MULTIVARIATE ANALYSIS; ORTHOPEDIC SURGERY; PAIN; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOTHERAPY; RETROSPECTIVE STUDY; SECONDARY; SPINAL CORD COMPRESSION; SURGERY; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; KALLIKREINS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; ORTHOPEDIC PROCEDURES; PAIN; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; SPINAL CORD COMPRESSION;

EID: 85007504666     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30505     Document Type: Article

References (24)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–583.
3. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998−1999;17:331–336.
4. Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68:42–50.
5. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–1468.
6. McDougall JA, Bansal A, Goulart BH, et al. The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21:320–326.
7. Roghmann F, Antczak C, McKay RR, et al. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015;33:17.e9–e18.
8. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–1571.
9. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377:813–822.
10. Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26:368–374.
11. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
12. Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomized, phase 3 AFFIRM trial. Lancet Oncol. 2014;15:1147–1156.
13. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13:1210–1217.
14. Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology. 2010;76:1175–1181.
15. Moreira DM, Howard LE, Sourbeer KN, et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:333–337.
16. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159.
17. Hamilton RJ, Aronson WJ, Terris MK, et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008;179:1785–1789; discussion 1789-1790.
18. Howard LE, De Hoedt AM, Aronson WJ, et al. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2016;19:380–384.
19. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162–167.
20. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011;14:177–183.
21. Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. J Geriatr Oncol. 2014;5:281–289.
22. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Prognostic factors for skeletal complication from metastatic bone disease in breast cancer. Breast Cancer Res Treat. 2010;123:767–779.
23. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007;70:315–319.
24. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190:429–438.